AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31370975 — intervention group
Group type: COMPARATOR
Intervention: Dads 'n' Kids (DNK)
Number of subjects: 62
Study 28526233 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human KGF (palifermin 60 μg/kg)
Number of subjects: 60
Study 28526233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 60
Study 25304965 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 130
Study 25304965 — intervention group
Group type: COMPARATOR
Intervention: Ice application
Number of subjects: 130
Study 25304965 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol
Number of subjects: 130
Study 23610448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (oral antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 0
Study 23610448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (oral antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 0
Study 23610448 — intervention group
Group type: EXPERIMENTAL
Intervention: DC101 (antibody targeting the VEGF pathway)
Number of subjects: 0
Study 23610448 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 0
Study 21931738 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback training
Number of subjects: 0
Study 21931738 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback from the left horizontal segment of the intraparietal sulcus (HIPS)
Number of subjects: 0
Study 17964811 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent with open eyes
Number of subjects: 0
Study 17964811 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent with sunglasses
Number of subjects: 0
Study 17964811 — intervention group
Group type: COMPARATOR
Intervention: Agent with closed eyes
Number of subjects: 0
Study 17964811 — intervention group
Group type: COMPARATOR
Intervention: Agent with occluders
Number of subjects: 0
Study 16537725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily for up to 8 days
Number of subjects: 12092
Study 12750950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus domperidone
Number of subjects: 953
Study 12750950 — intervention group
Group type: COMPARATOR
Intervention: Sennoside calcium
Number of subjects: 953
Study 12750950 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) lavage
Number of subjects: 953
Study 12750950 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in one 90‐ml dose
Number of subjects: 953
Study 12750950 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in 2 doses (90 ml + 45 ml)
Number of subjects: 953
Study 12750950 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus cisapride
Number of subjects: 953
Study 10977009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g American ginseng (AG)
Number of subjects: 10
Study 10977009 — intervention group
Group type: COMPARATOR
Intervention: 0 g (placebo)
Number of subjects: 10
Study 9125030 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 62
Study 9125030 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 62
Study 8477178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 11
Study 8477178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 11
Study 8477178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxitropium and fenoterol
Number of subjects: 11
Study 8477178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29897351 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (KM ≥ 2 mm)
Number of subjects: 42
Study 29897351 — intervention group
Group type: COMPARATOR
Intervention: Group B (KM < 2 mm)
Number of subjects: 42
Study 29897351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 30243811 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-Stepping Exercise (SSE) program
Number of subjects: 26
Study 30243811 — intervention group
Group type: COMPARATOR
Intervention: Minimal activity, attention-control condition
Number of subjects: 26
Study 27342494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + chemotherapy (LC)
Number of subjects: 0
Study 27342494 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy + placebo (CP)
Number of subjects: 0
Study 24894533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus tadalafil (group B)
Number of subjects: 244
Study 24894533 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (group A)
Number of subjects: 244
Study 22201336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose etizolam for 2 weeks
Number of subjects: 73
Study 22201336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 73
Study 17142005 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CF) with ropivacaine 0.2%
Number of subjects: 62
Study 17142005 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propacetamol (P) 2 g every 6 hours
Number of subjects: 62
Study 17142005 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine (M) 0.05 mg/kg every 4 hours
Number of subjects: 62
Study 16143283 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transplanted lung
Number of subjects: 0
Study 16143283 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study 16143283 — intervention group
Group type: EXPERIMENTAL
Intervention: External intercostal and external oblique muscles on the side of the transplanted lung
Number of subjects: 0
Study 12142304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed graded aerobic exercise
Number of subjects: 132
Study 12142304 — intervention group
Group type: COMPARATOR
Intervention: Relaxation and flexibility (control treatment)
Number of subjects: 132
Study 10215768 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL 0.1% in white soft paraffin applied twice daily for 2 weeks
Number of subjects: 11
Study 10215768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/mL ABL
Number of subjects: 11
Study 10215768 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 microg/mL ABL
Number of subjects: 11
Study 10215768 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg/mL ABL
Number of subjects: 11
Study 10215768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microg/mL ABL for 8 hours
Number of subjects: 11
Study 10215768 — intervention group
Group type: COMPARATOR
Intervention: Topical application of ABL 0.01% or 0.1%
Number of subjects: 11
Study 7554017 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding training course at SLC (18-day course)
Number of subjects: 8
Study 7554017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training course)
Number of subjects: 8
Study 2182960 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence Profile Method
Number of subjects: 0
Study 468096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastropulgit Tabs (2 tablets)
Number of subjects: 0
Study 468096 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (640 mg)
Number of subjects: 0
Study 30184165 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF (Doravirine 100 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734
Study 30184165 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734
Study 30184165 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF
Number of subjects: 734
Study 30184165 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 734
Study 30588965 — intervention group
Group type: EXPERIMENTAL
Intervention: pre‐HD preparatory program
Number of subjects: 100
Study 30588965 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 100
Study 26796709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low‐level laser therapy (LLLT) with passive stretching exercises
Number of subjects: 48
Study 26796709 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT with passive stretching exercises
Number of subjects: 48
Study 24664198 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder countertraction apparatus and physiotherapy (20 minutes a day for 5 days per week for 2 weeks)
Number of subjects: 100
Study 24664198 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 100
Study 24664198 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder countertraction apparatus and physiotherapy
Number of subjects: 100
Study 22120829 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin infusion 1 ng/kg/min
Number of subjects: 20
Study 22120829 — intervention group
Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 20
Study 22120829 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin infusion
Number of subjects: 20
Study 21070103 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning Mental Health First Aid training
Number of subjects: 262
Study 21070103 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Mental Health First Aid manual
Number of subjects: 262
Study 21070103 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 262
Study 17382029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual VEGF/EGFR inhibition (e.g., erlotinib and bevacizumab, or vandetanib)
Number of subjects: 0
Study 17382029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual VEGF/EGFR inhibition
Number of subjects: 0
Study 15005954 — intervention group
Group type: EXPERIMENTAL
Intervention: Table format presentation
Number of subjects: 100
Study 15005954 — intervention group
Group type: COMPARATOR
Intervention: Narrative format presentation
Number of subjects: 100
Study 11782829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation and antegrade electroejaculation for SCI group
Number of subjects: 30
Study 11782829 — intervention group
Group type: COMPARATOR
Intervention: Manual ejaculation for controls
Number of subjects: 30
Study 9832490 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 14
Study 9832490 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 14
Study 9832490 — intervention group
Group type: EXPERIMENTAL
Intervention: NO plus 50% oxygen
Number of subjects: 14
Study 9832490 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study 8585507 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape featuring positive deaf and hard of hearing role models
Number of subjects: 0
Study 2668787 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 and 600 mg per day
Number of subjects: 10
Study 2668787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 772669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40
Study 772669 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 40
Study 772669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pseudoephedrine and triprolidine
Number of subjects: 40
Study 772669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30189197 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI-bright
Number of subjects: 629
Study 30189197 — intervention group
Group type: COMPARATOR
Intervention: WLI
Number of subjects: 629
Study 28431747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training
Number of subjects: 23
Study 28431747 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 23
Study 26526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic position changes during colonoscope withdrawal
Number of subjects: 1072
Study 26526085 — intervention group
Group type: COMPARATOR
Intervention: Control group (left lateral position during colonoscope withdrawal)
Number of subjects: 1072
Study 25127885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 250
Study 25127885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 22203446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single-photon emission computed tomography (SPECT)
Number of subjects: 215
Study 22203446 — intervention group
Group type: COMPARATOR
Intervention: High-risk group without perfusion defect
Number of subjects: 215
Study 22203446 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 215
Study 22203446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT added to clinical and echocardiographic variables
Number of subjects: 215
Study 22203446 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 215
Study 19390123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose set at 80-110 mg/dL)
Number of subjects: 40
Study 19390123 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (blood glucose maintained at 180-200 mg/dL)
Number of subjects: 40
Study 17617204 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 26
Study 17617204 — intervention group
Group type: COMPARATOR
Intervention: Biliary drainage alone
Number of subjects: 26
Study 16638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Strip meniscometry
Number of subjects: 50
Study 16638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film lipid layer interferometry
Number of subjects: 50
Study 16638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film break‐up time measurement
Number of subjects: 50
Study 16638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular surface vital staining with fluorescein and rose bengal dyes
Number of subjects: 50
Study 16638996 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer‐1 test
Number of subjects: 50
Study 12008861 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (impulse magnetic-field therapy)
Number of subjects: 20
Study 12008861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin (PRL) treatment of RA synovial cells
Number of subjects: 0
Study 10493666 — intervention group
Group type: COMPARATOR
Intervention: Inhibitors of PRL release (e.g., bromocriptine)
Number of subjects: 0
Study 8740792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (O + D)
Number of subjects: 237
Study 8740792 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone plus lorazepam (M + D + L)
Number of subjects: 237
Study 1909241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg tds
Number of subjects: 22
Study 1909241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg tds
Number of subjects: 22
Study 1909241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg tds
Number of subjects: 22
Study 1909241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6309637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 45
Study 6309637 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg t.i.d.)
Number of subjects: 45
Study 31755917 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based remotely coached exercise group (n = 21)
Number of subjects: 34
Study 31755917 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n = 11)
Number of subjects: 34
Study 30235049 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT using 1%‐transdermal T‐gel (50 mg/day)
Number of subjects: 80
Study 27114091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine + saline
Number of subjects: 72
Study 27114091 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine/epinephrine + 1% ropivacaine
Number of subjects: 72
Study 27114091 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine/epinephrine + saline
Number of subjects: 72
Study 25904494 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥142 PACs per 24 hours at 6 months post-ablation
Number of subjects: 124
Study 25904494 — intervention group
Group type: EXPERIMENTAL
Intervention: PACs per 24 hours in patients with recurrence
Number of subjects: 124
Study 25904494 — intervention group
Group type: COMPARATOR
Intervention: PACs per 24 hours in patients without recurrence
Number of subjects: 124
Study 24176437 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 24176437 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo)
Number of subjects: 9340
Study 21430121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education regarding changing to reduced-fat dairy foods
Number of subjects: 93
Study 21430121 — intervention group
Group type: COMPARATOR
Intervention: Reducing screen time
Number of subjects: 93
Study 18937999 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once weekly for 24 weeks
Number of subjects: 20
Study 18937999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18937999 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20
Study 17456819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (1000 mg twice daily, initiated intravenously)
Number of subjects: 6560
Study 17456819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study 17456819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study 15135693 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (multivariate analysis to define independent predictors of mortality)
Number of subjects: 5679
Study 15135693 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score application in the validation group
Number of subjects: 5679
Study 15135693 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of mortality identified
Number of subjects: 5679
Study 11137727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led health education programme
Number of subjects: 0
Study 9737817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg four times daily for 21 doses)
Number of subjects: 20
Study 9737817 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Hydrochlorothiazide (combination)
Number of subjects: 20
Study 9737817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg twice daily for 11 doses)
Number of subjects: 20
Study 9737817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Diltiazem (combination)
Number of subjects: 20
Study 7812302 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC
Number of subjects: 54
Study 7812302 — intervention group
Group type: EXPERIMENTAL
Intervention: MVEEC
Number of subjects: 54
Study 2729379 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (454 +/- 4 mg caffeine)
Number of subjects: 8
Study 2729379 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (12 +/- 0.4 mg caffeine)
Number of subjects: 8
Study 31068398 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH (Interactive Behavior Change Technology)
Number of subjects: 488
Study 31068398 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH
Number of subjects: 488
Study 31068398 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH + PF (CTH plus brief practice facilitation)
Number of subjects: 488
Study 31068398 — intervention group
Group type: COMPARATOR
Intervention: SMS-ED (Self-Management Support Education)
Number of subjects: 488
Study 28490712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (1 to 30 mg)
Number of subjects: 0
Study 28490712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (1 to 100 mg or 5 mg twice daily)
Number of subjects: 0
Study 25499559 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment Response (AR)
Number of subjects: 0
Study 25499559 — intervention group
Group type: COMPARATOR
Intervention: Investigation Response (IR)
Number of subjects: 0
Study 23673101 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg/d)
Number of subjects: 178
Study 23673101 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (75 mg twice daily)
Number of subjects: 178
Study 19832873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 64
Study 19832873 — intervention group
Group type: COMPARATOR
Intervention: Seton
Number of subjects: 64
Study 19832873 — intervention group
Group type: EXPERIMENTAL
Intervention: Second injection of glue
Number of subjects: 64
Study 19832873 — intervention group
Group type: EXPERIMENTAL
Intervention: Seton treatment after glue failure
Number of subjects: 64
Study 19716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip
Number of subjects: 48
Study 19716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit‐G
Number of subjects: 48
Study 19716727 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 48
Study 19716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar Easymix
Number of subjects: 48
Study 19716727 — intervention group
Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 48
Study 19716727 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 48
Study 17477109 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking the mineralocorticoid receptor with anti-aldosterone agents
Number of subjects: 0
Study 15087637 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus nerve block with arm placed alongside body (group A)
Number of subjects: 52
Study 15087637 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus nerve block with arm in 90 degrees abduction (group B)
Number of subjects: 52
Study 15087637 — intervention group
Group type: COMPARATOR
Intervention: Brachial plexus nerve block
Number of subjects: 52
Study 11159256 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CMZ) 600 mg/d
Number of subjects: 43